480 related articles for article (PubMed ID: 33683582)
1. Cognitive Outcomes with Sequential Escitalopram Monotherapy and Adjunctive Aripiprazole Treatment in Major Depressive Disorder: A Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report.
Chakrabarty T; McInerney SJ; Torres IJ; Frey BN; Milev RV; Müller DJ; Rotzinger S; Kennedy SH; Lam RW;
CNS Drugs; 2021 Mar; 35(3):291-304. PubMed ID: 33683582
[TBL] [Abstract][Full Text] [Related]
2. Symptomatic and Functional Outcomes and Early Prediction of Response to Escitalopram Monotherapy and Sequential Adjunctive Aripiprazole Therapy in Patients With Major Depressive Disorder: A CAN-BIND-1 Report.
Kennedy SH; Lam RW; Rotzinger S; Milev RV; Blier P; Downar J; Evans KR; Farzan F; Foster JA; Frey BN; Giacobbe P; Hall GB; Harkness KL; Hassel S; Ismail Z; Leri F; McInerney S; MacQueen GM; Minuzzi L; Müller DJ; Parikh SV; Placenza FM; Quilty LC; Ravindran AV; Sassi RB; Soares CN; Strother SC; Turecki G; Vaccarino AL; Vila-Rodriguez F; Yu J; Uher R;
J Clin Psychiatry; 2019 Feb; 80(2):. PubMed ID: 30840787
[TBL] [Abstract][Full Text] [Related]
3. Influence of
Islam F; Magarbeh L; Elsheikh SSM; Kloiber S; Espinola CW; Bhat V; Frey BN; Milev R; Soares CN; Parikh SV; Placenza F; Hassel S; Taylor VH; Leri F; Blier P; Uher R; Farzan F; Lam RW; Turecki G; Foster JA; Rotzinger S; Kennedy SH; Müller DJ
Can J Psychiatry; 2024 Mar; 69(3):183-195. PubMed ID: 37796764
[TBL] [Abstract][Full Text] [Related]
4. Symptom Dimension of Interest-Activity Indicates Need for Aripiprazole Augmentation of Escitalopram in Major Depressive Disorder: A CAN-BIND-1 Report.
Uher R; Frey BN; Quilty LC; Rotzinger S; Blier P; Foster JA; Müller DJ; Ravindran AV; Soares CN; Turecki G; Parikh SV; Milev R; MacQueen G; Lam RW; Kennedy SH;
J Clin Psychiatry; 2020 Jun; 81(4):. PubMed ID: 32558407
[TBL] [Abstract][Full Text] [Related]
5. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants.
Berman RM; Fava M; Thase ME; Trivedi MH; Swanink R; McQuade RD; Carson WH; Adson D; Taylor L; Hazel J; Marcus RN
CNS Spectr; 2009 Apr; 14(4):197-206. PubMed ID: 19407731
[TBL] [Abstract][Full Text] [Related]
6. Pain severity and pain interference during major depressive episodes treated with escitalopram and aripiprazole adjunctive therapy: a CAN-BIND-1 report.
Diep C; Rosenek N; Khoo Y; Gandhi W; van Reekum CM; Ravindran AV; Ladha KS; Frey BN; Milev RV; Rotzinger S; Lam RW; Kennedy SH; Lou W; Salomons T; Bhat V
Psychiatry Res; 2022 Jun; 312():114557. PubMed ID: 35461118
[TBL] [Abstract][Full Text] [Related]
7. An investigation of cortical thickness and antidepressant response in major depressive disorder: A CAN-BIND study report.
Suh JS; Minuzzi L; Raamana PR; Davis A; Hall GB; Harris J; Hassel S; Zamyadi M; Arnott SR; Alders GL; Sassi RB; Milev R; Lam RW; MacQueen GM; Strother SC; Kennedy SH; Frey BN
Neuroimage Clin; 2020; 25():102178. PubMed ID: 32036277
[TBL] [Abstract][Full Text] [Related]
8. Predictors of Quality of Life Improvement with Escitalopram and Adjunctive Aripiprazole in Patients with Major Depressive Disorder: A CAN-BIND Study Report.
Morton E; Bhat V; Giacobbe P; Lou W; Michalak EE; McInerney S; Chakrabarty T; Frey BN; Milev RV; Müller DJ; Parikh SV; Rotzinger S; Kennedy SH; Lam RW;
CNS Drugs; 2021 Apr; 35(4):439-450. PubMed ID: 33860922
[TBL] [Abstract][Full Text] [Related]
9. Cognition and Its Association with Psychosocial and Occupational Functioning during Treatment with Escitalopram in Patients with Major Depressive Disorder: A CAN-BIND-1 Report: La Cognition Et Son Association Avec Le Fonctionnement Psychosocial Et Professionnel Durant Le Traitement Par Escitalopram Chez Des Patients Souffrant De Trouble Dépressif Majeur: Une Étude Can-Bind-1.
McInerney SJ; Chakrabarty T; Maciukiewicz M; Frey BN; MacQueen GM; Milev RV; Ravindran AV; Rotzinger S; Kennedy SH; Lam RW;
Can J Psychiatry; 2021 Sep; 66(9):798-806. PubMed ID: 33353384
[TBL] [Abstract][Full Text] [Related]
10. Impacts on Quality of Life with Escitalopram Monotherapy and Aripiprazole Augmentation in Patients with Major Depressive Disorder: A CAN-BIND Report.
Morton E; Bhat V; Giacobbe P; Lou W; Michalak EE; Chakrabarty T; Frey BN; Milev RV; Müller DJ; Parikh SV; Rotzinger S; Kennedy SH; Lam RW;
Pharmacopsychiatry; 2021 Sep; 54(5):225-231. PubMed ID: 33652477
[TBL] [Abstract][Full Text] [Related]
11. Discovering biomarkers for antidepressant response: protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohort.
Lam RW; Milev R; Rotzinger S; Andreazza AC; Blier P; Brenner C; Daskalakis ZJ; Dharsee M; Downar J; Evans KR; Farzan F; Foster JA; Frey BN; Geraci J; Giacobbe P; Feilotter HE; Hall GB; Harkness KL; Hassel S; Ismail Z; Leri F; Liotti M; MacQueen GM; McAndrews MP; Minuzzi L; Müller DJ; Parikh SV; Placenza FM; Quilty LC; Ravindran AV; Salomons TV; Soares CN; Strother SC; Turecki G; Vaccarino AL; Vila-Rodriguez F; Kennedy SH;
BMC Psychiatry; 2016 Apr; 16():105. PubMed ID: 27084692
[TBL] [Abstract][Full Text] [Related]
12. Effect of aripiprazole on promoting cognitive function and enhancing clinical efficacy in patients with first-episode depression on escitalopram: A randomized controlled trial.
Wang Y; Lu Z; Xun G
J Affect Disord; 2024 Jan; 344():159-168. PubMed ID: 37827257
[TBL] [Abstract][Full Text] [Related]
13. Response and remission rates with adjunctive aripiprazole in patients with major depressive disorder who exhibit minimal or no improvement on antidepressant monotherapy.
Casey DE; Laubmeier KK; Eudicone JM; Marcus R; Berman RM; Rahman Z; Sheehan J
Int J Clin Pract; 2014 Nov; 68(11):1301-8. PubMed ID: 25196314
[TBL] [Abstract][Full Text] [Related]
14. Pro-inflammatory markers are associated with response to sequential pharmacotherapy in major depressive disorder: a CAN-BIND-1 report.
Husain MI; Foster JA; Mason BL; Chen S; Zhao H; Wang W; Rotzinger S; Rizvi S; Ho K; Lam R; MacQueen G; Milev R; Frey BN; Müller D; Turecki G; Jha M; Trivedi M; Kennedy SH
CNS Spectr; 2023 Dec; 28(6):739-746. PubMed ID: 37218291
[TBL] [Abstract][Full Text] [Related]
15. Pretreatment anxious depression as a predictor of side effect frequency and severity in escitalopram and aripiprazole adjunctive therapy.
Espinola CW; Khoo Y; Parmar R; Demchenko I; Frey BN; Milev RV; Ravindran AV; Parikh SV; Ho K; Rotzinger S; Lou W; Lam RW; Kennedy SH; Bhat V;
Brain Behav; 2022 May; 12(5):e2555. PubMed ID: 35333448
[TBL] [Abstract][Full Text] [Related]
16. Cognitive-functional relationships in major depressive disorder: Crucial data from a Ukrainian open-label study of vortioxetine versus escitalopram.
Levada OA; Troyan AS
J Affect Disord; 2019 May; 250():114-122. PubMed ID: 30852363
[TBL] [Abstract][Full Text] [Related]
17. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study.
Berman RM; Marcus RN; Swanink R; McQuade RD; Carson WH; Corey-Lisle PK; Khan A
J Clin Psychiatry; 2007 Jun; 68(6):843-53. PubMed ID: 17592907
[TBL] [Abstract][Full Text] [Related]
18. The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder.
Boulton DW; Balch AH; Royzman K; Patel CG; Berman RM; Mallikaarjun S; Reeves RA
J Psychopharmacol; 2010 Apr; 24(4):537-46. PubMed ID: 18832427
[TBL] [Abstract][Full Text] [Related]
19. Distinct association of plasma BDNF concentration and cognitive function in depressed patients treated with vortioxetine or escitalopram.
Sagud M; Nikolac Perkovic M; Dvojkovic A; Jaksic N; Vuksan-Cusa B; Zivkovic M; Kusevic Z; Mihaljevic-Peles A; Pivac N
Psychopharmacology (Berl); 2021 Jun; 238(6):1575-1584. PubMed ID: 33560444
[TBL] [Abstract][Full Text] [Related]
20. Switching from Inadequate Adjunctive or Combination Treatment Options to Brexpiprazole Adjunctive to Antidepressant: An Open-Label Study on the Effects on Depressive Symptoms and Cognitive and Physical Functioning.
Fava M; Okame T; Matsushima Y; Perry P; Weiller E; Baker RA
Int J Neuropsychopharmacol; 2017 Jan; 20(1):22-30. PubMed ID: 27784751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
